Abstract
Abstract The outermost coating of every cell type is predominantly composed of cell-specific glycans, and glycosylation changes in cancer has been used in clinical field as a tumor markers, such including AFP and CA19-9. We focused pancreatic cancer, the most intractable cancer with difficulty in early diagnosis, and insisted to glasp glycosylation patterns by using a panel of lectin histochemical stainings. Lectins are subgroup of proteins that specifically recognize and bind glycans, and thus helpful indication of glycosylation patterns. Lectin microarry is one of the advanced technologies which inables glycosylation patters of target materials at onece, however, obtained data with homogenized protein matelials applied lacks histological location and information. Instead, we used a panel of 20 types of lectins histochemical staining for cancer and normal tissues. The staining patterns were firstlly classified according to the ratio between cancer cells and stromal cells. a) Cancer high (cancer cell ++ and stromal cells -) b) equal (cancer cells ++ or + and stromal cells ++ or +) c) Cancer Low (cancer cells - or + and stromal cells ++ or +). Further more, the stainig in cancer cell were compaired with that of non cancerous pancreatic ductal epitherial cells. Among 20 lectins, CNL, Clitocybe nebularis Lectin binds motifs containing α/βGalNAc, Tn antigen, and blood group A, showed cancer cell staining higher than normal tissue in pancreatic cancer. Pancreatic cancer cell (31 of 58 patients,71%) were positive for CNL, but normal pancreatic duct cells (2 of 42 patients,4%) were positive in patients of pancreatic cancer. CNL is known to recognize Tn Antigen in O-glycosylation. Previously, it reported that during malignancy, glycosylation displays abnormal expression of shortened or truncated glycans, such as a Tn antigen, T antigen and their sialylated forms, ST, STn antigen. CNL staining pattern we showed in this report is considered to matching Tn staining. Our result indicated that speccific affinity of CNL lectin in pancreatic cancer and counterpart glycoprotein are STn antigen. We may insist that STn glycoprotein antigen could be used as a diagnostic marker of Pancreatic cancer and also it would be a target of new tumor-targetting strategies. Citation Format: Yusuke Ozawa, Tatsuya Oda, Osamu Shimomura, Hiroaki Tateno, Jun Hirabayashi, Nobuhiro Ohkohchi. Pancreatic cancer specific glycosylations survay by a panel of lectin staining; Tn antigen exposure as a result of o-glycan truncation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5233. doi:10.1158/1538-7445.AM2017-5233
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
